View Financial HealthBeximco Pharmaceuticals 配当と自社株買い配当金 基準チェック /56Beximco Pharmaceuticals配当を支払う会社であり、現在の利回りは3.24%で、収益によって十分にカバーされています。主要情報3.2%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り8.1%配当成長17.6%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向24%最近の配当と自社株買いの更新お知らせ • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.お知らせ • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.お知らせ • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.すべての更新を表示Recent updatesお知らせ • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.お知らせ • Jun 22+ 2 more updatesBeximco Pharmaceuticals PLC. to Report Fiscal Year 2025 Results on Jun 23, 2026Beximco Pharmaceuticals PLC. announced that they will report fiscal year 2025 results on Jun 23, 2026お知らせ • Mar 06Beximco Pharmaceuticals PLC Provides Update on Writ PetitionsBeximco Pharmaceuticals PLC had provided an update regarding the timeline for its outstanding Writ Petitions to be heard by the High Court Division of the Supreme Court of Bangladesh. Further to previous announcements, the hearing of Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors) will now commence after the scheduled vacation (from March 15, 2026 to April 18, 2026) of the High Court Division of the Supreme Court of Bangladesh.お知らせ • Jan 29Beximco Pharmaceuticals Limited Announces Board ChangesBeximco Pharmaceuticals Limited announced that Ms. Quamrun Naher Ahmed, a Non-Executive Director since 30 November 2020, has been replaced by Mr. Mohammed Ebtadul Islam, both with immediate effect. Mr. Islam, like Ms. Ahmed previously, has been nominated to this position by IFIC Bank PLC, a shareholder in the Company, and he will serve as a Non-Executive Director. Mr. Islam has extensive expertise in finance and management at a senior level, having worked at Bangladesh Bank, the central bank of Bangladesh, for 33 years, retiring as an Executive Director in 2014. He currently serves as an independent director of IFIC Bank PLC. He is also a Supernumerary Professor at the Bangladesh Institute of Bank Management (BIBM), the national educational institute on banking and finance in Bangladesh.お知らせ • Jan 23Beximco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 28, 2025Beximco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 28, 2025お知らせ • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.お知らせ • Nov 08Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Beximco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024お知らせ • Oct 30Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024, at 10:30 Central Asia Standard Time.お知らせ • Oct 23Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Beximco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024お知らせ • Apr 24Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024お知らせ • Jan 22Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024お知らせ • Jan 12Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing DirectorBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan MP as Managing Director with immediate effect. This follows an invitation from the Prime Minister for Mr. Hassan to join the newly formed Cabinet as a Minister after the recent Bangladesh Parliamentary Election on 7 January 2024.お知らせ • Jan 11Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the BoardBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan as Member of the Board with immediate effect. The process to find a replacement will commence immediately and the Company will provide an update at the appropriate time.お知らせ • Oct 30Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023Beximco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 05, 2023お知らせ • Oct 20+ 2 more updatesBeximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 10:30 Coordinated Universal Time.お知らせ • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.決済の安定と成長配当データの取得安定した配当: BXPの1株当たり配当金は過去10年間安定しています。増加する配当: BXPの配当金は過去10年間にわたって増加しています。配当利回り対市場Beximco Pharmaceuticals 配当利回り対市場BXP 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BXP)3.2%市場下位25% (GB)2.0%市場トップ25% (GB)5.3%業界平均 (Pharmaceuticals)2.6%アナリスト予想 (BXP) (最長3年)8.1%注目すべき配当: BXPの配当金 ( 3.24% ) はUK市場の配当金支払者の下位 25% ( 2.04% ) よりも高くなっています。高配当: BXPの配当金 ( 3.24% ) はUK市場の配当金支払者の上位 25% ( 5.29% ) と比較すると低いです。株主への利益配当収益カバレッジ: BXPは低い 配当性向 ( 24.5% ) であるため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: BXPの 現金配当性向 ( 30.7% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YGB 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/10 19:07終値2026/08/10 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Beximco Pharmaceuticals PLC. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Asif KhanEDGE Research & ConsultingLorenza CastellonEquity Development LimitedZareen ShahjahanIDLC Securities Limited
お知らせ • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.
お知らせ • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.
お知らせ • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.
お知らせ • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.
お知らせ • Jun 22+ 2 more updatesBeximco Pharmaceuticals PLC. to Report Fiscal Year 2025 Results on Jun 23, 2026Beximco Pharmaceuticals PLC. announced that they will report fiscal year 2025 results on Jun 23, 2026
お知らせ • Mar 06Beximco Pharmaceuticals PLC Provides Update on Writ PetitionsBeximco Pharmaceuticals PLC had provided an update regarding the timeline for its outstanding Writ Petitions to be heard by the High Court Division of the Supreme Court of Bangladesh. Further to previous announcements, the hearing of Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors) will now commence after the scheduled vacation (from March 15, 2026 to April 18, 2026) of the High Court Division of the Supreme Court of Bangladesh.
お知らせ • Jan 29Beximco Pharmaceuticals Limited Announces Board ChangesBeximco Pharmaceuticals Limited announced that Ms. Quamrun Naher Ahmed, a Non-Executive Director since 30 November 2020, has been replaced by Mr. Mohammed Ebtadul Islam, both with immediate effect. Mr. Islam, like Ms. Ahmed previously, has been nominated to this position by IFIC Bank PLC, a shareholder in the Company, and he will serve as a Non-Executive Director. Mr. Islam has extensive expertise in finance and management at a senior level, having worked at Bangladesh Bank, the central bank of Bangladesh, for 33 years, retiring as an Executive Director in 2014. He currently serves as an independent director of IFIC Bank PLC. He is also a Supernumerary Professor at the Bangladesh Institute of Bank Management (BIBM), the national educational institute on banking and finance in Bangladesh.
お知らせ • Jan 23Beximco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 28, 2025Beximco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 28, 2025
お知らせ • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.
お知らせ • Nov 08Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Beximco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024
お知らせ • Oct 30Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024, at 10:30 Central Asia Standard Time.
お知らせ • Oct 23Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Beximco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024
お知らせ • Apr 24Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024
お知らせ • Jan 22Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024
お知らせ • Jan 12Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing DirectorBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan MP as Managing Director with immediate effect. This follows an invitation from the Prime Minister for Mr. Hassan to join the newly formed Cabinet as a Minister after the recent Bangladesh Parliamentary Election on 7 January 2024.
お知らせ • Jan 11Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the BoardBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan as Member of the Board with immediate effect. The process to find a replacement will commence immediately and the Company will provide an update at the appropriate time.
お知らせ • Oct 30Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023Beximco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 05, 2023
お知らせ • Oct 20+ 2 more updatesBeximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 10:30 Coordinated Universal Time.
お知らせ • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.